+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rheumatology Therapeutics Market by Therapeutic Class (Conventional Dmards, Il-6 Inhibitors, Jak Inhibitors), Molecule Type (Biologics, Biosimilars, Small Molecules), Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030- Product Image
Rheumatology Therapeutics Market by Therapeutic Class (Conventional Dmards, Il-6 Inhibitors, Jak Inhibitors), Molecule Type (Biologics, Biosimilars, Small Molecules), Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Rheumatology Therapeutics Market by Therapeutic Class (Conventional Dmards, Il-6 Inhibitors, Jak Inhibitors), Molecule Type (Biologics, Biosimilars, Small Molecules), Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011655
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The rheumatology therapeutics market is rapidly evolving as technological innovations and patient-focused strategies reshape clinical practice and commercial priorities. Senior leaders are presented with new opportunities to drive impact across product development, market access, and patient engagement.

Market Snapshot: Rheumatology Therapeutics Market Growth

In 2024, the rheumatology therapeutics market was valued at USD 33.24 billion, reaching USD 35.45 billion in 2025. It is projected to expand at a CAGR of 6.54%, reaching USD 48.62 billion by 2030. This growth reflects the sector’s shift from traditional immunosuppressive approaches to advanced targeted therapies and digital health integration.

Scope & Segmentation

This report assesses the full value chain and competitive landscape, covering product types, innovations, key regions, and distribution channels driving transformation in the market.

  • Therapeutic Classes: Conventional DMARDs (Hydroxychloroquine, Leflunomide, Methotrexate, Sulfasalazine), IL-6 Inhibitors, JAK Inhibitors, TNF Inhibitors
  • Molecule Types: Biologics, Biosimilars, Small Molecules
  • Indications: Ankylosing Spondylitis, Gout, Psoriatic Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus
  • Routes of Administration: Intravenous, Oral, Subcutaneous
  • Patient Age Groups: Adult, Pediatric
  • Distribution Channels: Offline, Online
  • Geography Covered: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Players: AbbVie Inc., Johnson & Johnson, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, UCB S.A.
  • Enabling Technologies: Precision medicine, digital health platforms, AI-powered diagnostics, biosimilars development, real-world data integration

Key Takeaways for Decision-Makers

  • Integrated digital health platforms and AI-driven tools are driving earlier diagnosis, streamlined monitoring, and adaptive patient management across the care continuum.
  • The competitive landscape is shaped by a surge in biosimilars adoption and intensified value-based procurement, requiring robust differentiation strategies.
  • Collaborative models between global biopharmaceutical leaders, regional biotech firms, and academic research centers are accelerating the launch of personalized therapeutic options.
  • Supply chain resilience and agile pricing strategies are essential as procurement landscapes and reimbursement frameworks evolve in response to policy shifts.
  • Geographic and regulatory dynamics present distinct opportunities, with North America focusing on early innovation access, Europe on biosimilar integration, Middle East and Africa on healthcare investment, and Asia-Pacific emphasizing digital outreach and localized manufacturing.

Tariff Impact and Market Response

The 2025 United States tariff regime is reshaping supply chain and pricing dynamics in rheumatology therapeutics. Increased costs for imported active ingredients and manufacturing equipment are prompting manufacturers to reevaluate sourcing, negotiate long-term procurement agreements, and consider near-shoring solutions. Pricing and reimbursement committees must balance cost containment with timely patient access, fueling discussions around value-based contracting and innovative pricing models. Organizational agility in supply chain configuration will influence future competitive positioning.

Methodology & Data Sources

This report uses a mixed-method approach, combining qualitative interviews with rheumatology clinicians, payers, and patient advocates, and quantitative analysis from proprietary databases and published literature. Expert panels, survey data, and secondary research were triangulated to ensure credibility and minimize bias throughout every research phase.

Why This Report Matters

  • Enables data-driven portfolio optimization and identification of emerging therapeutic opportunities in an increasingly complex market.
  • Supports strategic planning by offering granular insight into regulatory, technological, and regional trends underpinning decision-making for commercial leaders.
  • Guides resource allocation for R&D, market access, and patient engagement platforms by quantifying the implication of external policy shifts and technology adoption.

Conclusion

Comprehensive insights into rheumatology therapeutics enable industry leaders to adapt strategies, engage target populations, and anticipate regulatory or policy risks. This report provides practical frameworks for sustained success in a changing therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of real-world data and AI-driven analytics to optimize biologic therapy selection for rheumatoid arthritis patients
5.2. Emergence of biosimilar interchangeability guidelines accelerating cost-effective access to TNF inhibitors in rheumatology
5.3. Development of JAK inhibitor safety monitoring protocols in response to emerging cardiovascular and malignancy risk data
5.4. Adoption of patient-reported outcome digital platforms to personalize treatment adherence in chronic autoimmune disorders
5.5. Advances in targeted small molecule design enabling next-generation therapies for refractory psoriatic arthritis cases
5.6. Regulatory approvals of novel IL-17 and IL-23 inhibitors reshaping treatment algorithms in axial spondyloarthritis management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rheumatology Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Conventional Dmards
8.2.1. Hydroxychloroquine
8.2.2. Leflunomide
8.2.3. Methotrexate
8.2.4. Sulfasalazine
8.3. Il-6 Inhibitors
8.4. Jak Inhibitors
8.5. Tnf Inhibitors
9. Rheumatology Therapeutics Market, by Molecule Type
9.1. Introduction
9.2. Biologics
9.3. Biosimilars
9.4. Small Molecules
10. Rheumatology Therapeutics Market, by Indication
10.1. Introduction
10.2. Ankylosing Spondylitis
10.3. Gout
10.4. Psoriatic Arthritis
10.5. Rheumatoid Arthritis
10.6. Systemic Lupus Erythematosus
11. Rheumatology Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Rheumatology Therapeutics Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Rheumatology Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.3. Online
14. Americas Rheumatology Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Rheumatology Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Rheumatology Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Johnson & Johnson
17.3.3. Novartis AG
17.3.4. Roche Holding AG
17.3.5. Pfizer Inc.
17.3.6. Amgen Inc.
17.3.7. Eli Lilly and Company
17.3.8. Sanofi S.A.
17.3.9. Bristol-Myers Squibb Company
17.3.10. UCB S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. RHEUMATOLOGY THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. RHEUMATOLOGY THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. RHEUMATOLOGY THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. RHEUMATOLOGY THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RHEUMATOLOGY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 102. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 103. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 104. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 105. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 112. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 113. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 116. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 117. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 188. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 189. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 190. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 191. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 198. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 199. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 202. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 203. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 204. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 205. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 212. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 213. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 230. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 231. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 232. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 233. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 234. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 235. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 244. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 245. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 246. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 247. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 254. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 255. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 300. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 301. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 302. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 303. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 304. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 305. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • Roche Holding AG
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • UCB S.A.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 35.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 48.62 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Rheumatology Therapeutics - Global Strategic Business Report - Product Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Rheumatology Therapeutics Market Report 2025 - Product Image

Rheumatology Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Rheumatoid Arthritis Treatment - Global Strategic Business Report - Product Image

Rheumatoid Arthritis Treatment - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Interleukin Inhibitors for the Treatment of Refractory Gout Market by Product, End User, Route Of Administration, Distribution Channel, Dosage Form, Treatment Setting, Patient Category - Global Forecast 2025-2030 - Product Image

Interleukin Inhibitors for the Treatment of Refractory Gout Market by Product, End User, Route Of Administration, Distribution Channel, Dosage Form, Treatment Setting, Patient Category - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From

About the Anti Rheumatic Market

The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.